Physician profile
Jacob Caylor
NPI 1013370717
$98,932.49
in general payments reported to CMS, 2019-2025
26 companies · $3,365 in 2025
The $3,365 reported for 2025 was more than what 87% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $9,639 · 2021: $6,354 · 2022: $18K · 2023: $38K · 2024: $23K · 2025: $3,365.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $45K · Food and Beverage: $14K · Travel and Lodging: $5,307 · Consulting Fee: $495.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $44,770.00 |
| Food and Beverage | $14,154.43 |
| Travel and Lodging | $5,306.59 |
| Consulting Fee | $495.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $75,230.23 | 2021-2025 | Intellis Adaptivestim, Vanta Adaptivestim, Kyphon Express II Kyphopak Tray |
| Boston Scientific Corporation | $7,325.37 | 2020-2025 | General - Pain Management, Wavewriter Alpha Prime 16 |
| Abbott Laboratories | $4,675.70 | 2021-2025 | Proclaim, Octrode, Eterna |
| Medtronic USA, INC. | $4,328.80 | 2020 | |
| Globus Medical, INC. | $2,200.17 | 2025 | Senza, Omnia |
| Nevro Corp. | $1,437.02 | 2021-2024 | Senza |
| Nalu Medical, INC. | $949.83 | 2021-2024 | Nalu Neurostimulation System |
| Spinal Simplicity, LLC | $922.77 | 2022-2024 | Ha Minuteman G3-R |
| Painteq LLC | $844.15 | 2022-2024 | Painteq |
| Relievant Medsystems, INC. | $347.75 | 2022-2023 | Intracept |
| Zynex Medical, INC. | $131.04 | 2025 | Nexwave |
| Abbvie INC. | $59.96 | 2022-2023 | Qulipta |
| Tersera Therapeutics LLC | $57.78 | 2024-2025 | Prialt |
| Spr Therapeutics, INC | $53.86 | 2022-2023 | Sprint Pns System |
| Biohaven Pharmaceutical Holding Company LTD. | $53.60 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $48.83 | 2021-2022 | |
| Radius Health, INC. | $48.83 | 2021-2022 | |
| Vertex Pharmaceuticals Incorporated | $44.24 | 2025 | |
| Amgen INC. | $39.24 | 2021-2022 | |
| Vertos Medical, INC. | $32.48 | 2021 | |
| Lundbeck LLC | $24.09 | 2020 | |
| Si-Bone, INC. | $19.61 | 2022 | |
| Collegium Pharmaceutical, INC. | $16.46 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.66 | 2022 | |
| Biodelivery Sciences International, INC. | $12.65 | 2021 | |
| Lilly USA, LLC | $12.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Caylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.